摘要
目的探讨重组人血管内皮抑制素注射液(商品名:恩度)联合化疗治疗中晚期肺腺癌的临床效果。方法 80例中晚期肺腺癌患者,采用随机数字表法分为对照组和实验组,各40例。对照组接受常规化疗治疗,实验组接受恩度联合化疗治疗。比较两组患者的治疗效果、不良反应发生情况及治疗后3、6、12个月的生存率。结果实验组总缓解率为97.50%,明显高于对照组的82.50%,差异具有统计学意义(P<0.05)。实验组不良反应发生率为20.00%,低于对照组的47.50%,差异具有统计学意义(P<0.05)。治疗后3个月,两组生存率比较差异无统计学意义(P>0.05);治疗后6、12个月,实验组生存率分别为87.50%、75.00%,明显高于对照组的50.00%、22.50%,差异具有统计学意义(P<0.05)。结论恩度联合化疗治疗中晚期肺腺癌不仅能够有效提升患者的肿瘤总缓解率及生存率,且还能降低不良反应发生率,值得临床推广应用。
Objective To discuss the clinical effect of recombinant human endostatin injection(trade name:Endo)combined with chemotherapy in the treatment of advanced lung adenocarcinoma.Methods A total of 80 patients with advanced lung adenocarcinoma were divided into control group and experimental group according to random numerical table,with 40 cases in each group.The control group was treated with conventional chemotherapy,and the experimental group was treated with Endo and chemotherapy.The therapeutic effect,occurrence of adverse reactions,and survival rate after 3,6 and 12 months of treatment were compared between the two groups.Results The total remission rate of the experimental group was 97.50%,which was obviously higher than 82.50%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the experimental group was 20.00%,which was lower than 47.50%of the control group,and the difference was statistically significant(P<0.05).After 3 months of treatment,there was no statistically significant difference in survival rate between the two groups(P>0.05).After 6 and 12 months of treatment,the survival rate of the experimental group were 87.50%and 75.00%,which were obviously higher than 50.00%and 22.50%of the control group,and the difference was statistically significant(P<0.05).Conclusion Combination of Endo and chemotherapy can not only effectively improve the remission rate of tumor,but also lower the incidence of adverse reactions,and it is worthy of clinical promotion and application.
作者
吴幸谕
李劲
程典文
吴成焱
黄光位
WU Xing-yu;LI Jin;CHENG Dian-wen(Department of Internal Medicine-Oncology,Yangjiang People’s Hospital,Yangjiang 529500,China)
出处
《中国实用医药》
2021年第22期37-39,共3页
China Practical Medicine
基金
恩度联合化疗治疗中晚期肺腺癌的临床研究(项目编号:阳科通[2019]50号之22)。
关键词
重组人血管内皮抑制素注射液
化疗
中晚期肺腺癌
Recombinant human endostatin injection
Chemotherapy
Advanced lung adenocarcinoma
